SEC Form 4
Attovia Therapeutics, Inc. (ATTO) insider trading
In the 12 months to Nov 19, 2026, 2 ATTO insiders reported open-market sales of $4.5M across 2 filings; 6 insiders bought $52.4M.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $4.5M
- 2 filings · 2 insiders
- Open-market purchases
- $52.4M
- 6 filings
Who traded ATTO, and when
- Purchase
- Sale
ATTO daily close from Aug 5, 2026 to Nov 18, 2026, between $13.73 and $25.55, last $15.53. 2 sale and 6 purchase filings by 6 insiders, marked at their filing dates. Broad Street Principal Investments, L.L.C., Other: sold $2.3M and bought $10.3M across 2 filings, first filed Aug 28, 2026, last Aug 28, 2026. Colin Walsh, Director: sold $2.3M and bought $10.3M across 2 filings, first filed Aug 28, 2026, last Aug 28, 2026. Jeremy Green, 10% owner: bought $10.2M across 1 filing, first filed Aug 7, 2026, last Aug 7, 2026. FHMLS XI, L.L.C., 10% owner: bought $10.0M across 1 filing, first filed Aug 6, 2026, last Aug 6, 2026. venBio Global Strategic Fund IV, L.P., 10% owner: bought $6.5M across 1 filing, first filed Aug 10, 2026, last Aug 10, 2026. Sanofi, 10% owner: bought $5.1M across 1 filing, first filed Aug 7, 2026, last Aug 7, 2026.
Largest mark · tap a row for others
Broad Street Principal Investments, L.L.C. · Other
Purchase $10,285,000
585,000 shares at $17.58 avg
Filed Aug 28, 2026 · traded Aug 5
Close on filing date $20.70
Broad Street Principal Investments, L.L.C. · Other
Other
$2.3M sold$10.3M boughtColin Walsh · Director
Director
$2.3M sold$10.3M boughtJeremy Green · 10% owner
10% owner
$10.2M boughtFHMLS XI, L.L.C. · 10% owner
10% owner
$10.0M boughtvenBio Global Strategic Fund IV, L.P. · 10% owner
10% owner
$6.5M boughtSanofi · 10% owner
10% owner
$5.1M boughtOpen-market trades
8 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Broad Street Principal Investments, L.L.C. | Other | $2.3M | $10.3M | 2 | — | |
| Colin Walsh | Director | $2.3M | $10.3M | 2 | — | |
| Jeremy Green | 10% owner | — | $10.2M | 1 | — | |
| FHMLS XI, L.L.C. | 10% owner | — | $10.0M | 1 | — | |
| venBio Global Strategic Fund IV, L.P. | 10% owner | — | $6.5M | 1 | — | |
| Sanofi | 10% owner | — | $5.1M | 1 | — |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Broad Street Principal Investments, L.L.C. Other | Sale | 105,807 | $21.28 | $2.3M | 62,374 | |
traded | Broad Street Principal Investments, L.L.C. Other | Purchase | 585,000 | $17.58 | $10.3M | 3,020,632 | |
traded | Colin Walsh Director | Sale | 105,807 | $21.28 | $2.3M | 74,870 | |
traded | Colin Walsh Director | Purchase | 585,000 | $17.58 | $10.3M | 3,020,632 | |
traded | venBio Global Strategic Fund IV, L.P. 10% owner | Purchase | 382,352 | $17.00 | $6.5M | 4,181,367 | |
traded | Jeremy Green 10% owner | Purchase | 600,000 | $17.00 | $10.2M | Multiple accounts | |
traded | Sanofi 10% owner | Purchase | 300,000 | $17.00 | $5.1M | 1,082,855 | |
traded | FHMLS XI, L.L.C. 10% owner | Purchase | 588,235 | $17.00 | $10.0M | 6,154,213 |
GET /stocks/filings/vX/form-4?tickers=ATTO&filing_date.gte=2025-11-19&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"ATTO"
],
"issuer_cik": "0002058707",
"owner_cik": "0002148329",
"accession_number": "0000886982-26-000522",
"form_type": "4/A",
"filing_date": "2026-08-28",
"period_of_report": "2026-08-05",
"issuer_name": "Attovia Therapeutics, Inc.",
"issuer_trading_symbol": "ATTO",
"owner_name": "WSLS EMP OFFSHORE INVESTMENTS, L.P.",
"is_director": false,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": true,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-08-06",
"transaction_code": "P",
"equity_swap_involved": false,
"transaction_shares": 500000,
"transaction_price_per_share": 17,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 3020632,
"transaction_value": 8500000,
"date_of_original_submission": "2026-08-13",
"not_subject_to_section_16": true,
"direct_or_indirect": "I",
"nature_of_ownership": "See Footnotes",
"footnotes": [
{
"id": "F4",
"description": "The previous report on Form 3 reflected an administrative error with respect to the number of shares of common stock issuable upon conversion of the Preferred Stock, which is corrected in this Form 4."
},
{
"id": "F1",
"description": "Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."
},
{
"id": "F2",
"description": "These transactions in or with respect to the common stock of the Issuer were effected by Goldman Sachs & Co. LLC (\"GS&Co\") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer."
}
]
},
{
"tickers": [
"ATTO"
],
"issuer_cik": "0002058707",
"owner_cik": "0002148330",
"accession_number": "0000886982-26-000522",
"form_type": "4/A",
"filing_date": "2026-08-28",
"period_of_report": "2026-08-05",
"issuer_name": "Attovia Therapeutics, Inc.",
"issuer_trading_symbol": "ATTO",
"owner_name": "WSLS OFFSHORE INVESTMENTS, SLP",
"is_director": false,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": true,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-08-05",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 100,
"transaction_price_per_share": 21.99,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 62374,
"transaction_value": 2199,
"date_of_original_submission": "2026-08-13",
"not_subject_to_section_16": true,
"direct_or_indirect": "I",
"nature_of_ownership": "See Footnotes",
"footnotes": [
{
"id": "F1",
"description": "Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."
},
{
"id": "F2",
"description": "These transactions in or with respect to the common stock of the Issuer were effected by Goldman Sachs & Co. LLC (\"GS&Co\") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer."
},
{
"id": "F3",
"description": "GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 14 records
- Other14 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
- Counted once
- When several owners (a fund and its partners, say) report the same trade, it's counted once. Corrected filings replace the originals.
Frequently asked questions
Has Attovia Therapeutics, Inc.'s CEO sold stock?
No. Tao Fu and Attovia Therapeutics, Inc. (CEOs) made no open-market sales filed as CEO in the last 12 months.
How current is ATTO’s insider data?
These are ATTO Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track ATTO insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for ATTO every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.